

1 **Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid,**
2 **spike protein domain 1 and neutralizing antibodies**

3

4 **Short title**

5 SARS-CoV-2 seroconversion screening and antibody stability

6

7 **Authors**

8 Anja Garritsen^{1,#,+}, Anja Scholzen^{1,#}, Daan W.A. van den Nieuwenhof¹, Anke P.F. Smits¹, E. Suzan
9 Datema¹, Luc S. van Galen¹, Milou L.C.E. Kouwijzer¹

10

11 # Authors contributed equally

12 ⁺ Corresponding author: anja.garritsen@innatoss.com, Kloosterstraat 9 RE21, Room 3124, 5349 AB
13 Oss, The Netherlands

14

15

16 **Affiliations**

17 ¹Innatoss Laboratories B.V., Oss, The Netherlands

18

19 **Abstract**

20 Serological testing in the COVID-19 pandemic is mainly implemented to gain sero-epidemiological
21 data, but can also retrospectively inform about suspected SARS-CoV-2 infection. We verified and
22 applied a two-tiered testing strategy combining a SARS-CoV-2 receptor-binding domain (RBD)-
23 specific lateral flow assay (LFA) with a nucleocapsid protein (NCP) IgG ELISA to assess seroconversion
24 in n=7241 individuals. The majority had experienced symptoms consistent with COVID-19, but had
25 no access to RT-PCR testing. Longitudinal follow-up in n=97 LFA+ individuals was performed up to 20
26 weeks after initial infection using NCP and spike protein S1 domain (S1) IgG ELISAs and a surrogate
27 virus neutralization test (sVNT). Individuals reporting symptoms from January 2020 onwards showed
28 seroconversion, as did a considerable proportion of asymptomatic individuals. Seroconversion for
29 symptomatic and asymptomatic individuals was higher in an area with a known infection cluster
30 compared to a low incidence area. Overall, 94% of individuals with a positive IgG result by LFA were
31 confirmed by NCP ELISA. The proportion of ELISA-confirmed LFA results declined over time, in line
32 with contracting NCP IgG titers during longitudinal follow-up. Neutralizing antibody activity was
33 considerably more stable than S1 and NCP IgG titers, and both reach a plateau after approximately
34 100 days. The sVNT proved to be not only highly specific, but also more sensitive than the specificity-
35 focussed two-tiered serology approach. Our results demonstrate the high specificity of two-tiered
36 serology testing and highlight the sVNT used as a valuable tool to support modelling of SARS-CoV-2
37 transmission dynamics, complement molecular testing and provide relevant information to
38 individuals.

39

40 **Keywords**

41 SARS-CoV-2, serology, lateral flow assay, ELISA, longevity, neutralizing antibodies

42 Introduction

43 The novel coronavirus SARS-CoV-2 is the causative agent of the worldwide pandemic of coronavirus
44 disease 2019 (COVID-19), which has led to millions of infections with substantial morbidity and
45 mortality [1]. COVID-19 is characterized by a range of symptoms including cough, fever, pneumonia
46 and a characteristic loss of smell and taste [2, 3]. The clinical manifestations of COVID-19 differ
47 considerably and range from asymptomatic or mild self-limiting disease to severe disease and death.
48 Next to co-morbidities predisposing to severe disease, immune hyperresponsiveness appears to be a
49 critical factor driving COVID-19 disease severity [4, 5].

50 In the Netherlands, the spread of SARS-CoV-2 started in the Southern provinces, likely exacerbated
51 by regional carnival celebrations following travel to and from Northern Italy during the school
52 holidays [6, 7]. However, due to limited capacity at the time RT-PCR testing for SARS-CoV-2 was
53 largely restricted to hospitalized patients with suspected COVID-19 and symptomatic individuals
54 with moderate disease that had a recent travel history to high risk areas such as Northern Italy. Even
55 household members of RT-PCR positive individuals were advised to self-isolate but not tested.
56 Therefore, a large number of symptomatic individuals in The Netherlands were not tested for SARS-
57 CoV-2 up until the start of July 2020, which left many affected individuals uncertain about whether
58 or not their symptoms were due to COVID-19. Serological testing offers a possibility to abolish this
59 uncertainty. In an early study, it was shown that seroconversion for anti-SARS-CoV-2 IgG and IgM
60 occurred simultaneously or sequentially within 19 days of infection in all symptomatic COVID-19
61 patients analyzed [8]. The receptor-binding domain (RBD) of the spike protein of coronaviruses is a
62 particularly interesting target for serological testing since it is the target of neutralizing antibodies [9-
63 11], and serology tests based on the detection of these antibodies are being evaluated as indicators
64 of protective immunity.

65 A crucial requirement when offering individualized serological testing, however, is a very high
66 specificity of the test(s) selected to avoid false positives. At the early stage of the pandemic, the risk
67 and benefit of serological tests and in particular rapid tests such as lateral flow assays (LFAs) was
68 heavily debated [12]. Next to concerns about the performance of such rapid tests, another worry
69 was poor registration and potential misinterpretation of the results of these tests outside controlled
70 laboratory settings [13].

71 Following careful verification of a range of CE-marked serological test, Innatoss started in April 2020
72 to offer testing for SARS-CoV-2 antibodies in a mobile lab setting using finger prick blood. LFA results
73 were interpreted by trained staff and applied in the context of a two-tiered testing strategy to
74 maximize specificity. This testing strategy combined an RBD-directed LFA with strong performance

75 characteristics [14] with a highly specific anti-SARS-CoV-2 nucleocapsid protein (NCP) IgG ELISA for
76 confirmation in follow-up serum samples. This dual test approach is in line with the recommended
77 common practice for serologic testing of Lyme Borreliosis, which also serves to enhance specificity
78 [15]. Pre-screening with an LFA reduces pressure on the general health care system since it abolishes
79 the need for venous blood collection, which is then only necessary for LFA positive individuals for
80 confirmatory ELISA.

81 Here, we report the verification, performance and outcomes of this two-tiered serological testing
82 strategy applied in n=7241 individuals from mid-April to mid-August in The Netherlands. The
83 majority of these individuals had experienced symptoms consistent with COVID-19 at least 4 weeks
84 prior to testing. Our results demonstrate the high specificity and feasibility of this testing approach
85 even in times of strict anti-COVID-19 lock-down measures. We further described the kinetics of anti-
86 SARS-CoV-2 NCP and spike protein domain 1 (S1) IgG levels as well neutralizing antibodies measured
87 using a surrogate virus neutralization test (sVNT) [16] in a subgroup of individuals that underwent
88 diagnostic follow-up up to 20 weeks after initial infection. These data demonstrate that neutralizing
89 antibodies are highly stable in the time frame analyzed and that the sVNT used provides not only a
90 very specific but also highly sensitive and scalable assay to follow-up seroconverted individuals to
91 determine functional antibody responses to SARS-CoV-2.

92 **Materials and methods**

93 ***Sample collection***

94 All blood/serum samples and data reported in this article were submitted to Innatoss for diagnostic
95 purposes. All individuals whose data are reported in this article provided written consent to the use
96 of pseudonymized test outcomes and of surplus serum samples for additional analyses. The Medisch
97 Ethische Toetsingscommissie Brabant, Tilburg, The Netherlands has waived the need for IRB
98 approval of reuse of surplus diagnostics materials (NW2020-77).

99 For the verification of the specificity of the serological tests in March and April 2020, up to n=224
100 Dutch negative control serum samples (collected before November 2019) were used. These were
101 derived from subjects tested for different diseases at Innatoss, who had given consent to re-use the
102 sample for quality control purposes. n=85 serum samples were tested in all tests verified. To acquire
103 positive control samples for sensitivity verification, n=21 Dutch individuals with a past positive RT-
104 PCR for SARS-CoV-2 as well as clinical symptoms (fever, cough) were invited to participate in the
105 verification process and donated blood by finger prick for LFA assessment. n=11 of these individuals
106 also donated blood by venipuncture to obtain serum samples for IgG ELISA sensitivity verification;
107 only 6 of these were also available for IgA ELISA verification.

108 Whole blood samples were obtained with a finger prick in Dutch individuals with suspicion of a
109 recently experienced SARS-CoV-2 infection. A mobile laboratory unit enabled the collection of
110 samples in various regions of the Netherlands without violating the COVID-19 behavioural
111 guidelines. To ensure that sufficient time had passed (>4 weeks after symptom onset) and thus that
112 antibody responses were detectable, individuals filled in a questionnaire. This questionnaire further
113 included the onset, end and type of symptoms they experienced prior to applying for the serological
114 test (common cold symptoms, cough, fever, pneumonia, loss of smell or taste). Individuals were
115 encouraged to only get tested at the mobile laboratory when they had experiencing symptoms, and
116 were required to be symptom-free for at least 2 weeks prior to testing. Additionally, some
117 individuals without symptoms requested testing when either a family member had experienced
118 symptoms or when larger groups were tested for screening purposes within a company.

119 When individuals had a positive LFA test, they were invited to undergo a venipuncture to obtain a
120 serum sample. This sample was used for measuring anti-SARS-CoV-2 antibodies by NCP ELISA. A
121 second serum sample was collected from interested individuals for diagnostic follow-up. This
122 included a group of n=97 individuals from the Dutch village of Kessel in the province of Limburg,
123 which experienced a local SARS-CoV-2 outbreak likely in the context of a meeting with hundreds of
124 attendees on 5 March 2020.

125 To verify potential cross-reactivity of the serological tests, n=23 serum samples were used including
126 13 samples from an internal collection of Dutch donors which were sero-positive one or more of the
127 following pathogens: *C. Pneumoniae*, *M. Pneumoniae*, *Coxiella burnetii*, *Toxoplasma*, *Legionella*, EBV,
128 HSV-1, CMV, Parvo virus B19). Additionally, n=10 serum samples were purchased from ProMedDx
129 (Norton, Massachusetts, USA; n=4 human anti-mouse antibody (HAMA); n=6 rheumatoid factor
130 (RF)). The negative control serum samples used for initial verification further included n=13 with an
131 old and n=3 with a recent *Borrelia* infection.

132 **Serological tests**

133 Whole blood obtained by finger prick was tested in two commercial CE-marked LFAs: The BIOSYNEX
134 COVID-19 BSS using the SARS-CoV-2 receptor binding domain (RBD) as a target antigen (BIOSYNEX,
135 Fribourg, Switzerland) and the Xiamen Boson rapid 2019-nCoV IgG/IgM Combo test using both the
136 RBD and the SARS-CoV-2 nuclear capsid protein (NCP) (Xiamen Boson Biotech, Xiamen, China). The
137 outcomes of the LFAs were scored positive or negative based on whether the IgG/IgM and control
138 band were visible with the naked eye. Within the visibility, a division was made between ‘clearly
139 visible’ and “almost invisible” to distinguish in a later phase whether the intensity of the band
140 related to the levels of antibody detected by ELISA.

141 Follow-up serum samples were tested with two commercial CE-marked semi-quantitative ELISAs:
142 The EUROIMMUN SARS-CoV-2 IgG – S1 ELISA, which uses the S1 domain and the EUROIMMUN SARS-
143 CoV-2 IgG – NCP ELISA, modified to only contain diagnostically relevant epitopes (both from
144 EUROIMMUN, Lübeck, Germany). Some samples were additionally tested using the *recomWell* SARS-
145 CoV-2 IgG ELISA detecting antibodies directed against SARS-CoV-2 NCP (Mikrogen, Neuried,
146 Germany). The EUROIMMUN SARS-CoV-2 IgA – S1 ELISA was also tested. However, during
147 verification this test showed a specificity of only 89% and was therefore excluded from further
148 analysis. The outcomes of the ELISAs were scored as follows according to the manufacturer’s
149 guidelines: The EUROIMMUN ELISA results are calculated as a ratio by dividing the optical density
150 (OD) of the sample by the OD of the calibrator (Negative <0.8; 0.8 ≤ Borderline ≤ 1.1; positive >1.1).
151 The Mikrogen ELISA outcomes are expressed in arbitrary units calculated as $(OD_{\text{sample}} / OD_{\text{cut-off control}})$
152 $\times 20$, and test results interpreted as: Negative < 20; 20 ≤ Borderline ≤ 24; Positive > 24.

153 A subset of left-over serum samples was additionally tested using a CE-marked surrogate virus
154 neutralization assay (sVNT, cPassTM, GenScript, Nanjing, China) for verification and comparison
155 purposes. The cPassTM sVNT quantifies antibodies of any isotype that interfere with the binding of
156 the SARS-CoV-2 RBD to surface-immobilized angiotensin-converting enzyme (ACE)2. The outcome of

157 cPass™ was expressed as the relative level of inhibition with a cut-off value of 0.2 (equivalent to 20%
158 inhibition). The relative level of inhibition was calculated as $1 - (OD_{\text{sample}} / OD_{\text{negative control}})$.

159 Finally, some individual serum samples were tested for verification and cross-reactivity using the
160 *recomLine* SARS-CoV-2 IgG immunoblot (Mikrogen, Neuried, Germany) incorporating the SARS-CoV-
161 2 NCP, S1 domain and RBD domain as well as the NCP of the four endemic coronaviruses (CoV) 229E,
162 NL63, OC43 and HKU1. The immunoblot score was evaluated by scoring the intensity of the bands
163 with the naked eye as no reaction, borderline or positive.

164 All of these tests were performed according to the manufacturer's instructions. Claimed and verified
165 characteristics of the assays are summarized in **Supporting Table S1**.

166

167 ***Statistical analysis***

168 Statistical analysis was performed using GraphPad Prism v8 (San Diego, CA, US).

169 RESULTS

170 Selection of tests for two-tiered SARS-CoV-2 serology assessment

171 To select the most appropriate tests for the two-tiered SARS-CoV-2 serology assessment, a number
172 of CE-marked diagnostic tests including two different LFAs and four different ELISAs were verified for
173 their specificity and sensitivity using pre-corona serum samples and samples from individuals that
174 tested positive by RT-PCR for SARS-CoV-2, respectively (**Supporting Table S1 and Supporting Figure**
175 **S1A**). Based on these data, the BIOSYNEX LFA and the EUROIMMUN NCP IgG ELISA were selected as
176 the most appropriate tests with the highest specificity.

177 A panel of cross-reactivity serum samples known to be sero-positive for other pathogens, human
178 anti-mouse antibodies (HAMA) or rheumatoid factor (RF) was tested using the combination of
179 BIOSYNEX LFA and EUROIMMUN NCP IgG ELISA. All samples were scored negative using this two-
180 tiered approach. The only sample that tested false-positive in the BIOSYNEX LFA with positive IgM
181 band was the one of the six tested RF samples with the highest RF concentration (**Supporting Figure**
182 **S1B**). Of note, the BIOSYNEX LFA has elsewhere also been reported to cross-react with RF [14]. Given
183 that the false positive result in the RF serum sample by LFA was subsequently not confirmed in the
184 NCP ELISA, the combined specificity of these two tests was 100%.

185 Despite the high specificity of the selected tests in negative control samples, a recurring question
186 was whether tests would cross-react with endemic 'common' human coronaviruses (HCoV). Our
187 approach had been to use a large group of sera collected in 2019 prior to the SARS-CoV-2 pandemic,
188 and we assumed that a large proportion would be sero-positive for one or several of the HCoVs. In
189 contrast to other diseases, control sera for common coronaviruses are not easily available. To
190 demonstrate the presence of anti-HCoV antibodies in the collection of negative control sera, we
191 employed an immunoblot that includes NCP antigens from the four common HCoVs as well as the
192 SARS-CoV-2 NCP-antigen, the S1 antigen and the S1-RBD domain. This immunoblot was used to
193 assay any negative control sample that was false positive in one of the tests verified (n=17) as well as
194 n=9 negative control samples that were negative in all other tests. All samples tested were
195 (borderline) sero-positive for at least one of the HCoV, with the exception of a single S1 IgA false-
196 positive sample (**Supporting Figure S1C**).

197

198 *National and regional outcomes of the two-tiered SARS-CoV-2 serology assessment*

199 The two-tiered testing strategy to detect seroconversion for SARS-CoV-2 was offered in a mobile lab
200 setting for finger prick LFA testing, followed by laboratory analysis by ELISA in serum obtained from

201 those individuals with a positive LFA. In total there were n=7241 consenting individuals who were
202 tested by LFA between 14 April 2020 and 15 August 2020, including n=3156 males (43.6%), n=4028
203 females (55.6%) and n=57 unspecified individuals (0.8%). The age range of subjects was 2-95 years
204 (median 50 years, interquartile range (IQR) 40-59 years).

205 Due to supply chain issues for the BIOSYNEX LFA (the first shipment was confiscated by the French
206 authorities for priority national use), the first n=1611 individuals were tested using the Boson LFA,
207 knowing that the 2nd tier NCP IgG ELISA would filter out false positives (**Supporting Figure S1A**). Once
208 available in mid-May 2020, the BIOSYNEX LFA was phased in and used to test another n=5630
209 individuals (**Supporting Table S2**). Out of n=7241 individuals that were tested by LFA, n=1481
210 individuals tested positive by LFA (n=478 by Boson and n=1003 by BIOSYNEX). For both LFAs, 6-7% of
211 individuals failed to provide a follow-up serum sample for ELISA before August 15 (total n=97)
212 (**Figure 1**). The South of the Netherlands - in particular the province of North Brabant - was the
213 center of the initial spread of infection during the first phase of the SARS-CoV-2 pandemic, mainly
214 linked to travel to and from Northern Italy during the school holidays in the end of February 2020,
215 followed by regional carnival celebrations [6] (**Supporting Figure S2**). In line with this, the majority of
216 all individuals tested was from North Brabant (4300/7241 individuals; 59,4%). When analyzing the
217 results by area, individuals were more often positive by both LFA and NCP ELISA (35.9% of those with
218 symptoms and 8.9% of those without symptoms) in the hardly hit village of Kessel and surroundings
219 (situated in the municipality Peel en Maas in the province of Limburg) than in the area of Amsterdam
220 (15.4% of those with symptoms and 1.4% of those without; **Supporting Table S2** and **Figure 1**). This
221 is in line with the much higher incidence of notified COVID-19 cases in Peel and Maas, which is
222 particularly striking given the much higher population density in Amsterdam compared to the rural
223 municipality of Peel en Maas (**Supporting Figure S2C**).

224 Of note, although some individuals who requested serological testing reported symptoms as far back
225 as October 2019, positive LFA results confirmed by ELISA were only found for individuals who
226 reported symptoms from January 2020 onwards (**Supporting Figure S3A**). The highest proportion of
227 individuals with self-reported symptoms that tested positive by the 2-tiered LFA-ELISA strategy
228 reported symptoms in March-May 2020 (**Supporting Figure S3B**).

229 Focusing on the results of the more specific BIOSYNEX LFA, a change was noted over time from
230 samples being solitary IgM positive or IgG+IgM positive to solitary IgG positives (**Figure 2A**). LFA
231 IgG+IgM positives could be confirmed in the EUROIMMUN NCP IgG ELISA in 94% of the cases.
232 Confirmation of a solitary IgG positive band was lower (88.7%), except in the presence of a very clear
233 band in the BIOSYNEX LFA (93.7%; **Figure 2B**). Moreover, the proportion of BIOSYNEX LFA positive
234 samples that could not be confirmed by NCP IgG ELISA increased over time (**Figure 2C**).

235 When analyzing the data regardless of whether the LFA outcome was IgM+, IgM+ and IgG+, or IgG+
236 and whether a Boson or BIOSYNEX LFA was used for pre-screening, then out of all LFA+, 77.9% were
237 positive by SARS-CoV-2 NCP IgG ELISA (67,6% of Boson LFA+ and 82,8% of BIOSYNEX LFA+) and 3.9%
238 were borderline by NCP IgG ELISA (5.2% of Boson LFA+ and 3.3% of BIOSYNEX LFA+). Moreover, 11%
239 of positive LFA results were tested negative by NCP ELISA (21.1% of Boson LFA+ and 7.2% of
240 BIOSYNEX LFA+; **Supporting Table S2**). The overall lower percentages (compared to the high
241 confirmation rates of IgG+IgM or solitary IgG+ BIOSYNEX results, **Figure 2**) are partly due to the fact
242 that an IgG ELISA was used also to confirm results with a solitary IgM band. Moreover, these results
243 confirm that the Boson LFA is less specific than the BIOSYNEX LFA and highlight the advantage of the
244 two-tiered strategy of combining an LFA for screening and an ELISA for confirmation of a positive
245 result, especially when used in combination with a less specific LFA. Not surprisingly, positive results
246 were more common in individuals that reported symptoms (18% LFA+ and ELISA+; 0.9% LFA+ and
247 ELISA borderline) than in those that did not (5% LFA+ and ELISA+; 0.5% LFA+ and ELISA borderline).
248 Those who failed to report whether they had experienced symptoms or not were clearly a mixed
249 group with 8.8% LFA+ELISA+ and 0.4% LFA+ELISA borderline.

250

251 ***Stability of SARS-CoV-2 specific antibody responses***

252 As outlined earlier, the village of Kessel and its surrounding experienced a local SARS-CoV-2 outbreak
253 likely linked to a meeting with hundreds of participants on 5 March 2020. n=97 individuals from this
254 area who were sero-positive in the first round of serological testing (positive LFA followed by ELISA)
255 returned for diagnostic follow-up 19-93 days after the first measurement, enabling longitudinal
256 analysis of antibody levels. Out of these 97 individuals, 89 reported symptoms, 7 reported no
257 symptoms and 1 made no report. 86/89 individuals with self-reported symptoms specified a date of
258 symptom onset, mostly in calendar weeks 9-12 (24 February – 22 March 2020; **Figure 3A**). The first
259 serological testing was performed 39-144 days (median 65 days, IQR 55-75 days) after the onset of
260 symptoms. There was no correlation between the time lapsed from symptom onset until the first
261 serological test on the one hand, and the level of antibodies or antibody-mediated inhibition on the
262 other hand (**Supporting Figure S4**). Therefore, the absolute level of antibodies and the degree of
263 antibody-mediated inhibition did not depend on how long after the onset of symptoms the first
264 serological test was conducted.

265 Based on this and the fact that the outbreak occurred in a short window of time, changes in antibody
266 levels in the interval from first to second serological assessment were analyzed for the group as a
267 whole, regardless of the exact time of symptom onset or whether individuals reported symptoms or
268 not. While anti-SARS-CoV-2 NCP and S1 IgG levels declined significantly over time between the first

269 and second measurement, this decline was not observed for the level of antibody-mediated
270 inhibition measured by sVNT (**Figure 3B**). For further analysis, the change in the level of specific
271 antibodies and antibody-mediated inhibition was calculated as $\log[\text{test1}] - \log[\text{test2}]$, and an increase
272 or decrease of 0.1 was considered a substantial change. When focusing on n=85 individuals with an
273 interval of >6 weeks (47-93 days) between the two test time points, it was evident that anti-NCP IgG
274 and anti-S1 IgG levels declined significantly more than the antibody-mediated inhibition of RBD-
275 ACE2 interaction. In contrast, antibody levels measured by all three testes were stable within a
276 shorter time interval of 2-5 weeks (19-35 days) (**Figure 3C**). In this latter group of n=12 individuals,
277 10 reported symptoms and the first serological test was carried out much later after SARS-CoV-2
278 infection, 102-144 days after symptom onset (median 108; IQR 105-117 days) compared to 39-103
279 days after symptom onset (median 63, IQR 54-69 days) in the former group. Overall, within an
280 interval of >6 weeks there was a decline in SARS-CoV-2 specific IgG antibodies in 65% and 75% of the
281 individuals tested for NCP and S1, respectively. In total, 91% of individuals tested showed a decline
282 in NCP and/or S1 IgG levels (77/85), in contrast to only 31% of the individuals when assessing
283 antibody-mediated inhibition measured by sVNT (**Figure 3D**). The number of individuals that were
284 scored positive at the first and second measurement was 77/85 versus 71/85 by NCP IgG ELISA,
285 83/85 versus 73/85 by S1 IgG ELISA and 85/85 versus 83/85 by sVNT, stressing the stability of the
286 sVNT results.

287 Already in the verification phase with negative control samples collected in 2019 as well as serum
288 samples from SARS-CoV-2 RT-PCR+ individuals, the sVNT proved to be both highly specific and
289 sensitive. Performance of this functional assay was further evaluated with a random selection of
290 serum samples acquired from the mobile lab setting from n=60 LFA negative and 206 LFA positive
291 individuals in a side-by-side comparison with the BIOSYNEX LFA, EUROIMMUN NCP and S1 IgG
292 ELISAs (**Supporting Figure S5**). In this analysis, 8/60 LFA negative individuals had a low positive result
293 in the sVNT assay (level of inhibition 20-54%; median 32%). It was already known from the BIOSYNEX
294 LFA verification that this rapid test is only ~90% sensitive, as it misses 2/20 individuals with a prior
295 RT-PCR confirmed SARS-CoV-2 infection. In contrast, the sVNT was able to identify all 11/11 positive
296 control samples tested. Moreover, of the 206 BIOSYNEX LFA positive serum samples, 25 were
297 negative and 6 were borderline by NCP IgG ELISA. In contrast, only 15/206 BIOSYNEX LFA positive
298 serum samples were negative by sVNT, all but one of which were negative by NCP IgG ELISA. These
299 data therefore show that the highly specific and sensitive sVNT assay is able to identify additional
300 samples that contain functional anti-SARS-CoV2 antibodies that are missed when using the
301 BIOSYNEX RBD LFA for pre-screening or the NCP IgG ELISA for confirmation. This confirms the lower
302 sensitivity of those two tests, alone and in combination, which were in fact selected for their

- 303 excellent specificity. Not surprisingly, inhibition levels of RBD-ACE2 interaction measured by sVNT
- 304 correlated more strongly with anti-S1 IgG levels than with NCP IgG level (**Supporting Figure S6**).

305 Discussion

306 In this study, we report the verification, performance and outcomes of a two-tiered serological
307 testing strategy combining a SARS-CoV-2 RBD-specific LFA with a confirmatory NCP IgG ELISA to
308 assess seroconversion in n=7241 individuals, the majority of which had experienced symptoms
309 consistent with COVID-19, but had no access to RT-PCR testing. Using this highly specific testing
310 approach that showed no cross-reactivity with endemic HCoVs, we demonstrate that individuals
311 reporting symptoms as far back as January 2020 showed seroconversion to SARS-CoV-2. Although
312 individuals with past symptoms seroconverted more often than those without, a considerable
313 proportion of 5% of asymptomatic individuals also showed seroconversion, and this number was
314 higher in an area with a known infection cluster (8.9%) compared to a low incidence area (1.4%).
315 Overall, 94% of individuals with a positive IgG result by BIOSYNEX LFA were also confirmed by NCP
316 ELISA. Over time, the proportion of ELISA-confirmed LFA results declined, in line with contracting
317 NCP IgG titers during longitudinal diagnostic follow-up in a subgroup of individuals. We further find
318 that in contrast to S1 and NCP IgG titers, neutralizing antibody activity is a lot more stable, and that
319 both neutralizing antibody levels and S1 and NCP IgG levels reach a plateau after approximately 100
320 days. The sVNT used to assess SARS-CoV-2 neutralizing antibodies proved to be not only highly
321 specific, but also more sensitive to identify individuals with functional anti-SARS-CoV2 antibodies
322 that are missed using the specificity-focussed 2-tiered serology assessment.

323 Overall, our results demonstrate the feasibility of this two-tiered testing approach to retrospectively
324 inform individuals about the likely cause of their symptoms early during the pandemic when limited
325 RT-PCR testing capacities left many affected individuals uncertain about whether or not their
326 symptoms were due to COVID-19. We further demonstrate that this two-tiered strategy of
327 combining an LFA for screening and an ELISA for confirmation of a positive result is perfectly feasible
328 even when used in combination with a slightly less specific LFA such as the Boson Xiamen rapid test,
329 if supplies of a more specific LFA are limited. The high specificity of the BIOSYNEX LFA makes it an
330 interesting candidate rapid test to support molecular diagnosis or help triage suspected cases when
331 there is shortage of RT-PCR capacities to help avoid missing true cases of COVID-19 and imposing
332 unnecessary quarantine [17], as well as for source tracing by identifying seroconverted individuals in
333 transmission chains that have already cleared infection and are hence not anymore RT-PCR positive.

334 In the meantime, the focus has shifted for individuals from the question whether or not they had
335 been infected by SARS-CoV-2, to whether or not this prior infection and the mounted immune
336 response would provide them with protection against future infection and thus the risk for (severe)
337 COVID-19 and transmission of SARS-CoV-2 to others. With a potential second wave of infections
338 coming up, this question is not only relevant on an individual level, but also for policy makers and

339 health care authorities to determine how to optimally allocate potentially limited capacities for RT-
340 PCR testing and more importantly both source and contact tracing. Identifying individuals with
341 protective immunity using an easily scalable functional serological assay would allow for instance to
342 identify individuals that do not need to undergo repeated RT-PCR testing or self-isolate when
343 experiencing symptoms, and to release individuals from exposed clusters from quarantine measures.

344 Since early on in the COVID-19 pandemic, it has been suggested that serological tests could be used
345 to issue so-called 'immunity passports' [18-20]. This has caused heated discussions about potential
346 ethical, equitable and legal implications as well as public health ramifications due to potentially
347 increased/encouraged risky behavior by 'immunity passport' holders [17, 21]. One often used
348 argument in this context is that it is not yet established whether antibodies to SARS-CoV-2 confer
349 protective immunity to further infection, what amount of antibody is needed for protection or how
350 long any such immunity lasts. In the mean-time, a wealth of data has emerged that strongly supports
351 both the stability (as far as it can be evaluated up to now) and protective efficacy of neutralizing
352 antibodies to SARS-CoV-2.

353 In line with our findings, several studies have demonstrated that neutralizing antibodies as well as
354 anti-RBD IgG+ memory B-cells that can produce SARS-CoV-2 neutralizing antibodies are generated
355 and maintained in an encouragingly stable fashion for at least 3-4 months post-SARS-CoV-2 infection
356 [22-26]. Some studies have noted a contraction in levels of anti-SARS-CoV-2 IgG antibodies including
357 neutralizing SARS-CoV-2 antibody titers in the early convalescent phase up to 3 months after
358 symptom onset and even complete loss in individual cases [27-29]. However, the accumulating
359 evidence indicates that these early antibody dynamics likely only reflect the typical kinetics of a
360 primary immune response. In particular, SARS-CoV-2-specific IgG level described for a range of
361 individual patients show 'text book kinetics', with an initial peak followed by first a steep and then a
362 much more gradual decline [28]. Overall, IgM and IgA antibody responses against SARS-CoV-2 RBD,
363 S1 and NCP appear to contract rapidly until three months post symptom onset of COVID-19, while
364 circulating anti-SARS-CoV-2 IgG directed against these antigens remain much more stable [22, 24,
365 28]. Taking into account that IgA dominates the early neutralizing antibody response to SARS-CoV-2
366 [30] and that neutralizing activity can be observed before an IgG response to S1 and RBD is
367 detectable by ELISA, this strongly suggests that the initial decrease in neutralizing antibody activity
368 simply reflects the natural contraction of the short-lived plasma blast response, while a much
369 smaller population of long-lived plasma blasts is responsible for the continuous production of
370 circulating IgG antibodies [24, 31, 32]. Much in line with this is our observation that RBD-specific
371 responses detected by LFA convert from IgM to IgG over time, and that both anti-S1 and anti-NCP
372 IgG levels decrease when re-tested up to three months after symptom onset, while the levels of

373 antibody in follow-up samples obtained 102-144 days post symptom onset are stable. This suggests
374 that stable antibody levels are reached within 100 days post infection. That neutralizing antibody
375 levels showed a lesser contraction than NCP and S1 IgG levels might also be due to the affinity and
376 avidity of anti-RBD antibodies. For very high affinity and/or avidity antibodies, a plateau of
377 neutralizing activity may be reached, so that an initial contraction of anti-RBD antibodies is not yet
378 translating in the same degree of decline in neutralizing capacity.

379 One concern is that on the longer term, antibody responses to SARS-CoV-2 might show a pattern
380 similar to that of the four circulating (endemic) coronaviruses (HCoV-229E, OC43, NL63 and HKU1),
381 to which most individuals are exposed to and seroconvert for the first time during childhood [33,
382 34]. Antibodies to HCoVs return to baseline levels within one year after natural or controlled
383 infection [35-37] and challenge infection showed full homologous protection but only limited
384 heterologous protection after 1 year [37, 38]. As a result, a 2-3 year cyclic re-infection pattern for
385 endemic HCoVs is observed [34, 37, 38], which is consistent with waning neutralizing antibody titers
386 to levels that are no longer protective. For SARS-CoV, it was observed that 50% of former patients
387 lost detectable circulating anti-SARS-CoV antibody responses after 3 years [39]. In contrast to these
388 total opsonizing antibodies, however, serum samples collected from recovered SARS-CoV patients
389 17 years after the original infection still showed neutralizing activity against anti-SARS-CoV (8/10) by
390 sVNT [16]. This indicates that neutralizing antibody levels against this more closely to SARS-CoV-2
391 related coronavirus may be more long-lived. The longevity of the neutralizing antibody response to
392 SARS-CoV-2 will need to be determined by carefully designed longitudinal follow-up studies in
393 cohorts of seroconverted individuals like ours, ideally with prospective analysis of potential re-
394 infections. A modelling study of SARS-CoV-2 transmission has demonstrated how the duration of
395 immunity to SARS-CoV-2 infection determines whether or not SARS-CoV-2 enters into regular
396 circulation after the initial pandemic wave [40]. Of note, even a duration of 'only' two years
397 compared to one year of protection would already positively affect the total incidence of COVID-19
398 over the next five years. On a population level, sero-epidemiological data on neutralizing antibody
399 levels and their longevity are therefore crucial to support modelling the impact of preventative
400 measures and post-pandemic transmission dynamics [40, 41].

401 In regards to protective efficacy, several animal models have provided evidence that SARS-CoV-2
402 infection induces protective immunity against re-challenge in rhesus macaques, Syrian hamsters and
403 ferrets [42-45], and protection from disease could be linked to neutralizing antibodies (either
404 naturally induced or passively transferred) in the Syrian golden hamster model [44, 46, 47]. In
405 humans, neutralizing antibodies were shown to correlate with protection from SARS-CoV-2 during a
406 high attack rate fishery vessel outbreak, in which three sero-positive crewmembers were amongst

407 the few that did not contract infection [48]. And even in the event of re-infection, symptoms are
408 likely to be milder or even absent, as reported for the first documented case for SARS-CoV-2
409 reinfection [49]. Consequently, passive immunization using convalescent plasma or monoclonal
410 antibodies for SARS-CoV and SARS-CoV-2 is also pursued as therapeutic approach to treat critically ill
411 COVID-19 patients [50-57] and antibody neutralization assays are used as a key read-out in SARS-
412 CoV-2 vaccination trials in non-human primates and human clinical trials [58-62].

413 Finally, in hospitalized COVID-19 patients, it was further observed that upon seroconversion,
414 shedding of infectious SARS-CoV-2 dropped rapidly to undetectable levels. Infectious virus could not
415 be isolated from respiratory tract samples once patients had a serum neutralizing antibody titer of at
416 least 1:80 measured by plaque reduction neutralization test (PRNT), which may be due to the fact
417 that infectious virions are still produced but directly neutralized by antibodies in the respiratory
418 tract. Whether the same holds true for individuals with mild disease remains to be determined.
419 Nevertheless, the authors suggested that both quantitative viral RNA load assays and serological
420 assays should be used to monitor individuals to discontinue or de-escalate infection prevention and
421 control precautions [63].

422 While PRNTs are the gold standard for assessing functional antibody activity, these assays are labor-
423 intensive and require a biosafety level 3 laboratory. In contrast, the sVNT assay employed here is
424 scalable to high throughput use and has shown good agreement with PRNT [16], and has hence been
425 highlighted as an interesting alternative to PRNT to quantify functional antibodies [64]. This sVNT
426 also used in a recently published Australian study evaluating a range of serological tests for SARS-
427 CoV-2 [65]. This study reported slightly lower sensitivity values for the sVNT, likely due to the fact
428 that serum samples from convalescent Australian COVID-19 patients were collected at an earlier
429 time point in the convalescent phase. Indeed, they report a considerable increase in sVNT sensitivity
430 depending on whether serum samples were collected within 14 days or after 14 days of symptom
431 onset. In our study, all but 2/235 of the individuals with a reported date of symptom onset that were
432 tested by sVNT provided their serum samples at least 4 weeks after symptom onset (median 62
433 days, IQR 51-86 days). Ultimately, a key question to be answered in future studies is how the level
434 of inhibition measured by sVNT at a given serum dilution compares to the level of neutralizing
435 antibody required at which shedding of infectious virus is reduced to undetectable levels. This
436 information will be highly valuable for the interpretation of the sVNT test outcome in regards to
437 protection from future infection in an 'immunity passport' scenario. Given that it is not yet known
438 how long neutralizing antibodies to SARS-CoV-2 are stable and that this may also differ on an
439 individual level, periodic re-testing will likely be required.

440 There are some limitations to our study. Firstly, it should be highlighted that our data do not reflect
441 the seroconversion dynamics in the general population, since we encouraged individuals only to get
442 tested if they had experienced symptoms consistent with COVID-19. Even amongst this group, the
443 proportions of seroconversions we find are not representative for the whole of the Netherlands:
444 Although tests were performed in almost every region of the Netherlands, the majority of tests were
445 carried out in North Brabant (the most heavily affected area in March/April 2020) and Amsterdam.
446 Secondly, using the specificity-focussed two-tiered serological testing approach applied here, we
447 were bound to miss some individuals that had seroconverted. This is exacerbated over time by the
448 fact that NCP IgG levels contract and thus an increasing proportion of individuals that show a
449 positive result by RBD-LFA cannot be confirmed by NCP IgG ELISA. Using the sVNT in combination
450 with the RBD-LFA for pre-screening may partially alleviate this limitation. However, seeing the high
451 scalability of the sVNT in combination with both its high specificity and sensitivity (provided samples
452 are collected long enough after symptom onset), it can also simply be used as a stand-alone
453 screening tool. Thirdly, as any serological screening approach, the small proportion of individuals
454 which fail to seroconvert [23, 66] and instead only mount a cellular immune response to SARS-CoV-2
455 [67] will logically not be identified. Given that the degree of the antibodies seems to be related also
456 to disease severity, this may be particularly true for individuals with mild or asymptomatic infection
457 [27, 68]. Finally, while our data indicate that stable antibody levels are reached 100 days post
458 infection, the group of individuals that was assessed >100 days post symptom onset consisted of a
459 mere n=12 individuals. Therefore, analysis in larger groups is needed to support this finding.

460 In conclusion, we herein present a careful analysis of the performance of a two-tiered serological
461 testing approach to assess seroconversion and thus retrospectively confirm exposure to SARS-CoV-2.
462 Our data support that the highly specific LFA used in this combination approach may be useful also
463 in other settings, for instance to support or complement molecular testing and source tracing of
464 SARS-CoV-2 infection in transmission chains. Finally, we confirm other studies showing the stability
465 of neutralizing antibodies to SARS-CoV-2, and provide the first longitudinal assessment of these
466 antibodies using a highly scalable sVNT. This high specificity and sensitivity assay could thus be a
467 valuable tool for serological follow-up in large cohorts to support modelling of future SARS-CoV-2
468 transmission dynamics, support health authorities and provide relevant serological information to
469 individuals.

470 **Acknowledgements**

471 We acknowledge the continuous support of Stichting IMtest and in particular Dorien van Doorn on
472 the logistic challenges that we faced; Luc van Galen for setting up the MoLabs; Sanne van 't
473 Hullenaar and Saskia Theunisse for coordinating the MoLab appointments; Guido van de Wiel for
474 setting up the MoLab IT infrastructure; Kim Plaum for blood collections in the verification phase; and
475 the MoLab team consisting of Anna van Mólken, Laura van den Ende, Sarah van den As, Willem
476 Baijens, Laurens Bierens, Laurie Tiehuis, Koen van Maren, Sjoerd van der Burg, Sander Colijn, Daan
477 van den Nieuwenhof and Luc van Galen for running more than 8000 lateral flow tests and helping
478 with analyzing the clinical data. Jasper van Galen was instrumental in realizing timely reporting to all
479 the individuals involved. Finally, we acknowledge Liza van Oort (Mediphos Medical Supplies) for
480 support in a challenging environment.

481

482 **Authors contributions**

483 Conceptualization and design: AG, MLCEK. Acquisition of data: DWAvdN, APFS, ESD, LSvG. Analysis
484 and interpretation of data: AG, AS, DWAvdN, MLCEK. Drafting the article: AS, DWAvdN. Revision of
485 article: AG, MLCEK. All authors have read and approved the final manuscript.

486

487 **Conflict of interest**


488 AG is a senior officer and shareholder, and AS, DWAvdN, APFS, ESD, LSvG and MLCEK are employees
489 of Innatoss Laboratories B.V., which provides diagnostic screening for infectious diseases including
490 SARS-CoV-2.

491 **Figure legends**

492 **Figure 1 – SARS-CoV-2 LFA and NCP IgG ELISA results by area.** LFA and NCP ELISA results are shown
493 for n=7241 individuals that were tested by either Boson or BIOSYNEX LFA. N=97 individuals that
494 tested positive by LFA did not provide a follow-up serum sample for EUROIMMUN NCP IgG ELISA.
495 Data are shown as the proportion of individuals tested in the indicated areas, stratified depending
496 on whether or not symptoms were reported. Symptoms include common cold symptoms, cough,
497 fever, pneumonia, loss of smell or taste.


498 **Figure 2 – Confirmation of BIOSYNEX LFA results by EUROIMMUN NCP IgG ELISA.** BIOSYNEX LFA
499 results per month of testing (n=1003), stratified into individuals with solitary IgM or IgG bands or
500 IgM+IgG+ bands (A). IgG levels of anti-SARS-CoV-2 NCP were determined during 2nd tire serological
501 follow-up in n=935 individuals that were positive by BIOSYNEX LFA. The proportion of samples
502 negative, borderline or positive by NCP IgG ELISA is shown (B) for individuals with solitary IgM or IgG
503 bands, those with both IgM+ and IgG+ bands and separately for those with a strong solitary IgG
504 band, and for (C) all LFA IgM and/or IgG positive individuals per month of testing.

505 **Figure 3 – Stability of anti-NCP, anti-S1 and neutralizing antibodies.** (A) The number of individuals
506 who reported onset of symptoms is shown per calendar week. (B) The change in IgG levels of anti-
507 SARS-CoV-2 NCP and S1 antibodies as well as the level of inhibition conferred by anti-SARS-CoV-2
508 RBD-neutralizing antibodies are plotted against the time between first and second ELISA/sVNT for
509 n=97 SARS-CoV-2 sero-positive individuals regardless of presence or time of onset of reported
510 symptoms. Data were analyzed by Spearman correlation. (C) Change in anti-NCP or anti-S IgG
511 antibodies and anti-RBD neutralizing antibodies measured by sVNT in a time interval of ≤ 5 weeks
512 (n=12) and > 6 weeks (n=85) between first and second ELISA/sVNT. Data were analyzed by Friedman
513 test. *** $p < 0.0001$. (D) Proportion of individuals with declining, increasing or stable antibody levels
514 in the group with > 6 weeks (n=85) between first and second ELISA/sVNT. Changes in antibody levels
515 were calculated by subtraction of log values (test at time point 2 minus test at time point 1). An
516 increase or decrease of 0.1 was considered a substantial change. A change of less than 0.1 was
517 considered stable (grey shaded area in B and D).




518

519 *Figure 1 – SARS-CoV-2 LFA and NCP IgG ELISA results by area.*



520

521 *Figure 2 – Confirmation of BIOSYNEX LFA results by EUROIMMUN NCP IgG ELISA.*



522

523 *Figure 3 – Stability of anti-NCP, anti-S1 and neutralizing antibodies.*

524 References

- 525 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
526 time. *Lancet Infect Dis.* 2020;20(5):533-4. doi: 10.1016/S1473-3099(20)30120-1. PubMed PMID:
527 32087114; PubMed Central PMCID: PMC7159018.
- 528 2. Hasani H, Mardi S, Shakerian S, Taherzadeh-Ghahfarokhi N, Mardi P. The Novel Coronavirus
529 Disease (COVID-19): A PRISMA Systematic Review and Meta-Analysis of Clinical and Paraclinical
530 Characteristics. *Biomed Res Int.* 2020;2020:3149020. doi: 10.1155/2020/3149020. PubMed PMID:
531 32851061; PubMed Central PMCID: PMC7436291.
- 532 3. Dawson P, Rabold EM, Laws RL, Connors EE, Gharpure R, Yin S, et al. Loss of Taste and Smell
533 as Distinguishing Symptoms of COVID-19. *Clin Infect Dis.* 2020. doi: 10.1093/cid/ciaa799. PubMed
534 PMID: 32562541; PubMed Central PMCID: PMC7337666.
- 535 4. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of
536 severe and moderate coronavirus disease 2019. *J Clin Invest.* 2020;130(5):2620-9. doi:
537 10.1172/JCI137244. PubMed PMID: 32217835; PubMed Central PMCID: PMC7190990.
- 538 5. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19:
539 consider cytokine storm syndromes and immunosuppression. *Lancet.* 2020;395(10229):1033-4. doi:
540 10.1016/S0140-6736(20)30628-0. PubMed PMID: 32192578; PubMed Central PMCID:
541 PMC7270045.
- 542 6. Mc Intyre K, Lanting P, Deelen P, Wiersma H, Vonk JM, Ori AP, et al. The Lifelines COVID-19
543 Cohort: a questionnaire-based study to investigate COVID-19 infection and its health and societal
544 impacts in a Dutch population-based cohort. *medRxiv.* 2020:2020.06.19.20135426. doi:
545 10.1101/2020.06.19.20135426.
- 546 7. RIVM. Rijksinstituut voor volksgezondheid en milieu. Current information about COVID-19
547 (novel coronavirus). Update. 2020; <https://www.rivm.nl/en/novel-coronavirus-covid-19/currentinformation> (accessed Sept. 01, 2020).
- 549 8. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2
550 in patients with COVID-19. *Nat Med.* 2020;26(6):845-8. doi: 10.1038/s41591-020-0897-1. PubMed
551 PMID: 32350462.
- 552 9. He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S. Cross-neutralization of human and palm civet
553 severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding
554 domain of spike protein. *J Immunol.* 2006;176(10):6085-92. doi: 10.4049/jimmunol.176.10.6085.
555 PubMed PMID: 16670317.
- 556 10. Berry JD, Hay K, Rini JM, Yu M, Wang L, Plummer FA, et al. Neutralizing epitopes of the SARS-
557 CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. *MAbs.*
558 2010;2(1):53-66. doi: 10.4161/mabs.2.1.10788. PubMed PMID: 20168090; PubMed Central PMCID:
559 PMC2828578.
- 560 11. Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human
561 Coronaviruses. *Trends Immunol.* 2020;41(5):355-9. doi: 10.1016/j.it.2020.03.007. PubMed PMID:
562 32249063.
- 563 12. Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC, et al. Diagnostic
564 accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ.*
565 2020;370:m2516. doi: 10.1136/bmj.m2516. PubMed PMID: 32611558; PubMed Central PMCID:
566 PMC7327913.
- 567 13. GeurtsvanKessel CH, OKBA NMA, Igloi Z, Embregts CWE, Laksono BM, Leijten L, et al.
568 Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment.
569 *medRxiv.* 2020:2020.04.23.20077156. doi: 10.1101/2020.04.23.20077156.
- 570 14. Velay A, Gallais F, Benotmane I, Wendling MJ, Danion F, Collange O, et al. Evaluation of the
571 performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies.
572 *Diagnostic Microbiology and Infectious Disease.* 2020;pre-proof. Epub 21 Aug 2020. doi:
573 <https://doi.org/10.1016/j.diagmicrobio.2020.115181>.

- 574 15. Theel ES. The Past, Present, and (Possible) Future of Serologic Testing for Lyme Disease. *J*
575 *Clin Microbiol.* 2016;54(5):1191-6. doi: 10.1128/JCM.03394-15. PubMed PMID: 26865690; PubMed
576 Central PMCID: PMC4844714.
- 577 16. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus
578 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction.
579 *Nat Biotechnol.* 2020. doi: 10.1038/s41587-020-0631-z. PubMed PMID: 32704169.
- 580 17. Peeling RW, Wedderburn CJ, Garcia PJ, Boeras D, Fongwen N, Nkengasong J, et al. Serology
581 testing in the COVID-19 pandemic response. *Lancet Infect Dis.* 2020;20(9):e245-e9. doi:
582 10.1016/S1473-3099(20)30517-X. PubMed PMID: 32687805; PubMed Central PMCID:
583 PMC4844714.
- 584 18. Chen LH, Freedman DO, Visser LG. COVID-19 Immunity Passport to Ease Travel Restrictions?
585 *J Travel Med.* 2020;27(5). doi: 10.1093/jtm/taaa085. PubMed PMID: 32463093; PubMed Central
586 PMCID: PMC4844714.
- 587 19. Brown RCH, Savulescu J, Williams B, Wilkinson D. Passport to freedom? Immunity passports
588 for COVID-19. *J Med Ethics.* 2020. doi: 10.1136/medethics-2020-106365. PubMed PMID: 32817362.
- 589 20. de Walque D, Friedman J, Gatti R, Mattoo A. How two tests can help contain COVID-19 and
590 revive the economy. *Research & Policy Briefs World Bank Malaysia Hub.* 2020;29.
- 591 21. Phelan AL. COVID-19 immunity passports and vaccination certificates: scientific, equitable,
592 and legal challenges. *Lancet.* 2020;395(10237):1595-8. doi: 10.1016/S0140-6736(20)31034-5.
593 PubMed PMID: 32380041; PubMed Central PMCID: PMC4844714.
- 594 22. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Mucosal versus systemic antibody
595 responses to SARS-CoV-2 antigens in COVID-19 patients. *medRxiv.* 2020:2020.08.01.20166553. doi:
596 10.1101/2020.08.01.20166553.
- 597 23. Wajnberg A, Amanat F, Firpo A, Altman D, Bailey M, Mansour M, et al. SARS-CoV-2 infection
598 induces robust, neutralizing antibody responses that are stable for at least three months. *medRxiv.*
599 2020:2020.07.14.20151126. doi: 10.1101/2020.07.14.20151126.
- 600 24. Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PM, Thouvenel C, et al. Functional
601 SARS-CoV-2-specific immune memory persists after mild COVID-19. *medRxiv.*
602 2020:2020.08.11.20171843. doi: 10.1101/2020.08.11.20171843.
- 603 25. Perreault J, Tremblay T, Fournier M-J, Drouin M, Beaudoin-Bussi eres G, Pr evost J, et al.
604 Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma
605 donors. *bioRxiv.* 2020:2020.07.16.206847. doi: 10.1101/2020.07.16.206847.
- 606 26. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al.
607 Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med.* 2020. doi:
608 10.1056/NEJMoa2026116. PubMed PMID: 32871063.
- 609 27. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment
610 of asymptomatic SARS-CoV-2 infections. *Nat Med.* 2020. doi: 10.1038/s41591-020-0965-6. PubMed
611 PMID: 3255424.
- 612 28. Seow J, Graham C, Merrick B, Acors S, Steel KJA, Hemmings O, et al. Longitudinal evaluation
613 and decline of antibody responses in SARS-CoV-2 infection. *medRxiv.* 2020:2020.07.09.20148429.
614 doi: 10.1101/2020.07.09.20148429.
- 615 29. Liu A, Wang W, Zhao X, Zhou X, Yang D, Lu M, et al. Disappearance of antibodies to SARS-
616 CoV-2 in a -COVID-19 patient after recovery. *Clin Microbiol Infect.* 2020. doi:
617 10.1016/j.cmi.2020.07.009. PubMed PMID: 32653658; PubMed Central PMCID: PMC4844714.
- 618 30. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, et al. IgA dominates the early
619 neutralizing antibody response to SARS-CoV-2. *medRxiv.* 2020:2020.06.10.20126532. doi:
620 10.1101/2020.06.10.20126532.
- 621 31. Alter G, Seder R. The Power of Antibody-Based Surveillance. *N Engl J Med.* 2020. doi:
622 10.1056/NEJMe2028079. PubMed PMID: 32871061.
- 623 32. Stephens DS, McElrath MJ. COVID-19 and the Path to Immunity. *JAMA.* 2020. doi:
624 10.1001/jama.2020.16656. PubMed PMID: 32915201.

- 625 33. Zhou W, Wang W, Wang H, Lu R, Tan W. First infection by all four non-severe acute
626 respiratory syndrome human coronaviruses takes place during childhood. *BMC Infect Dis.*
627 2013;13:433. doi: 10.1186/1471-2334-13-433. PubMed PMID: 24040960; PubMed Central PMCID:
628 PMC3848659.
- 629 34. Monto AS. Medical reviews. Coronaviruses. *Yale J Biol Med.* 1974;47(4):234-51. PubMed
630 PMID: 4617423; PubMed Central PMCID: PMC2595130.
- 631 35. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to
632 experimental coronavirus infection of man. *Epidemiol Infect.* 1990;105(2):435-46. doi:
633 10.1017/s0950268800048019. PubMed PMID: 2170159; PubMed Central PMCID: PMC2271881.
- 634 36. Macnaughton MR. Occurrence and frequency of coronavirus infections in humans as
635 determined by enzyme-linked immunosorbent assay. *Infect Immun.* 1982;38(2):419-23. PubMed
636 PMID: 6292101; PubMed Central PMCID: PMC347755.
- 637 37. Reed SE. The behaviour of recent isolates of human respiratory coronavirus in vitro and in
638 volunteers: evidence of heterogeneity among 229E-related strains. *J Med Virol.* 1984;13(2):179-92.
639 doi: 10.1002/jmv.1890130208. PubMed PMID: 6319590; PubMed Central PMCID: PMC7166702.
- 640 38. Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al. Seasonal
641 coronavirus protective immunity is short-lasting. *Nat Med.* 2020. doi: 10.1038/s41591-020-1083-1.
642 PubMed PMID: 32929268.
- 643 39. Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, et al. Duration of antibody responses
644 after severe acute respiratory syndrome. *Emerg Infect Dis.* 2007;13(10):1562-4. doi:
645 10.3201/eid1310.070576. PubMed PMID: 18258008; PubMed Central PMCID: PMC2851497.
- 646 40. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission
647 dynamics of SARS-CoV-2 through the postpandemic period. *Science.* 2020;368(6493):860-8. doi:
648 10.1126/science.abb5793. PubMed PMID: 32291278; PubMed Central PMCID: PMC7164482.
- 649 41. Angulo FJ, Finelli L, Swerdlow DL. Reopening Society and the Need for Real-Time Assessment
650 of COVID-19 at the Community Level. *JAMA.* 2020. doi: 10.1001/jama.2020.7872. PubMed PMID:
651 32412582.
- 652 42. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, et al. SARS-CoV-2
653 infection protects against rechallenge in rhesus macaques. *Science.* 2020. doi:
654 10.1126/science.abc4776. PubMed PMID: 32434946.
- 655 43. Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, et al. Primary exposure to SARS-CoV-2 protects
656 against reinfection in rhesus macaques. *Science.* 2020;369(6505):818-23. doi:
657 10.1126/science.abc5343. PubMed PMID: 32616673; PubMed Central PMCID: PMC7402625.
- 658 44. Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, et al. Syrian
659 hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. *Proc*
660 *Natl Acad Sci U S A.* 2020;117(28):16587-95. doi: 10.1073/pnas.2009799117. PubMed PMID:
661 32571934; PubMed Central PMCID: PMC7368255.
- 662 45. Ryan KA, Bewley KR, Fotheringham SA, Brown P, Hall Y, Marriott AC, et al. Dose-dependent
663 response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge.
664 *bioRxiv.* 2020:2020.05.29.123810. doi: 10.1101/2020.05.29.123810.
- 665 46. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of potent SARS-CoV-2
666 neutralizing antibodies and protection from disease in a small animal model. *Science.*
667 2020;369(6506):956-63. doi: 10.1126/science.abc7520. PubMed PMID: 32540903; PubMed Central
668 PMCID: PMC7299280.
- 669 47. Haagmans BL, Noack D, Okba NMA, Li W, Wang C, Bestebroer T, et al. SARS-CoV-2
670 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model.
671 *bioRxiv.* 2020:2020.08.24.264630. doi: 10.1101/2020.08.24.264630.
- 672 48. Addetia A, Crawford KH, Dingens A, Zhu H, Roychoudhury P, Huang M, et al. Neutralizing
673 antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak
674 with high attack rate. *medRxiv.* 2020:2020.08.13.20173161. doi: 10.1101/2020.08.13.20173161.

- 675 49. To KK-W, Hung IF-N, Ip JD, Chu AW-H, Chan W-M, Tam AR, et al. COVID-19 re-infection by a
676 phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. *Clinical*
677 *Infectious Diseases*. 2020. doi: 10.1093/cid/ciaa1275.
- 678 50. Klasse PJ, Moore JP. Antibodies to SARS-CoV-2 and their potential for therapeutic passive
679 immunization. *Elife*. 2020;9. doi: 10.7554/eLife.57877. PubMed PMID: 32573433; PubMed Central
680 PMCID: PMC7311167.
- 681 51. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization
682 of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature*. 2020;583(7815):290-5. doi:
683 10.1038/s41586-020-2349-y. PubMed PMID: 32422645.
- 684 52. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in
685 severe COVID-19 patients. *Proc Natl Acad Sci U S A*. 2020;117(17):9490-6. doi:
686 10.1073/pnas.2004168117. PubMed PMID: 32253318; PubMed Central PMCID: PMC7196837.
- 687 53. Liu M, Chen Z, Dai MY, Yang JH, Chen XB, Chen D, et al. Lessons learned from early
688 compassionate use of convalescent plasma on critically ill patients with Covid-19. *Transfusion*. 2020.
689 doi: 10.1111/trf.15975. PubMed PMID: 32770691; PubMed Central PMCID: PMC7436937.
- 690 54. Olivares-Gazca JC, Priesca-Marin JM, Ojeda-Laguna M, Garces-Eisele J, Soto-Olvera S,
691 Palacios-Alonso A, et al. Infusion of Convalescent Plasma Is Associated with Clinical Improvement in
692 Critically Ill Patients with Covid-19: A Pilot Study. *Rev Invest Clin*. 2020;72(3):159-64. doi:
693 10.24875/RIC.20000237. PubMed PMID: 32584322.
- 694 55. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With
695 COVID-19 With Convalescent Plasma. *JAMA*. 2020. doi: 10.1001/jama.2020.4783. PubMed PMID:
696 32219428; PubMed Central PMCID: PMC7101507.
- 697 56. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients.
698 *BMJ*. 2020;368:m1256. doi: 10.1136/bmj.m1256. PubMed PMID: 32217555.
- 699 57. Shankar-Hari M, Estcourt L, Harvala H, Roberts D, Menon DK, United Kingdom S-C-CPEC.
700 Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised
701 clinical trials. *Crit Care*. 2020;24(1):449. doi: 10.1186/s13054-020-03163-3. PubMed PMID:
702 32690059; PubMed Central PMCID: PMC7370253.
- 703 58. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart SP, et al. Phase 1/2 Study to
704 Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults
705 18 to 55 Years of Age: Interim Report. *medRxiv*. 2020:2020.06.30.20142570. doi:
706 10.1101/2020.06.30.20142570.
- 707 59. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and
708 immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,
709 open-label, non-randomised, first-in-human trial. *Lancet*. 2020;395(10240):1845-54. doi:
710 10.1016/S0140-6736(20)31208-3. PubMed PMID: 32450106; PubMed Central PMCID:
711 PMC7255193.
- 712 60. Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, et al. A single-dose intranasal
713 ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. *Cell*. 2020. doi:
714 10.1016/j.cell.2020.08.026. PubMed PMID: PMC7437481.
- 715 61. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and
716 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a
717 phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020;396(10249):467-78. Epub
718 2020/07/24. doi: 10.1016/s0140-6736(20)31604-4. PubMed PMID: 32702298; PubMed Central
719 PMCID: PMC7445431.
- 720 62. van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, et
721 al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. *Nature*. 2020.
722 doi: 10.1038/s41586-020-2608-y. PubMed PMID: 32731258.
- 723 63. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al.
724 Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19):
725 duration and key determinants. *medRxiv*. 2020:2020.06.08.20125310. doi:
726 10.1101/2020.06.08.20125310.

- 727 64. GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An
728 evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. *Nat*
729 *Commun.* 2020;11(1):3436. doi: 10.1038/s41467-020-17317-y. PubMed PMID: 32632160; PubMed
730 Central PMCID: PMCPMC7338506.
- 731 65. Bond K, Nicholson S, Lim SM, Karapanagiotidis T, Williams E, Johnson D, et al. Evaluation of
732 serological tests for SARS-CoV-2: Implications for serology testing in a low-prevalence setting. *J Infect*
733 *Dis.* 2020. doi: 10.1093/infdis/jiaa467. PubMed PMID: 32761124; PubMed Central PMCID:
734 PMCPMC7454699.
- 735 66. Staines HM, Kirwan DE, Clark DJ, Adams ER, Augustin Y, Byrne RL, et al. Dynamics of IgG
736 seroconversion and pathophysiology of COVID-19 infections. *medRxiv.* 2020:2020.06.07.20124636.
737 doi: 10.1101/2020.06.07.20124636.
- 738 67. Gallais F, Velay A, Wendling M-J, Nazon C, Partisani M, Sibia J, et al. Intrafamilial Exposure
739 to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion. *medRxiv.*
740 2020:2020.06.21.20132449. doi: 10.1101/2020.06.21.20132449.
- 741 68. Liu L, To KK, Chan KH, Wong YC, Zhou R, Kwan KY, et al. High neutralizing antibody titer in
742 intensive care unit patients with COVID-19. *Emerg Microbes Infect.* 2020;9(1):1664-70. doi:
743 10.1080/22221751.2020.1791738. PubMed PMID: 32618497.

744